112 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Bristol-Myers Squibb (United States)US1 paper
- Celgene (United States)US1 paper
- Cerner (United States)US1 paper
- Eli Lilly (United States)US1 paper
- Genentech1 paper
- Janssen Research & Development (United States)US1 paper
- LinkedIn (United States)US1 paper
- Ludwig-Maximilians-Universität MünchenDE1 paper
- Merck & Co., Inc., Rahway, NJ, USA (United States)US1 paper
- NantOmics LLC (United States)US1 paper
- Nektar Therapeutics (United States)US1 paper
- Pfizer (United States)US1 paper
3 papers
Balancing events, not patients, maximizes power of the logrank test: and other insights on unequal randomization in survival trials
Godwin Yung, Kaspar Rufibach, Marcel Wolbers +2
We revisit the question of what randomization ratio (RR) maximizes power of the logrank test in event-driven survival trials under proportional hazards (PH). By comparing three app…
Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis
Ray S. Lin, Ji Lin, Satrajit Roychoudhury +16
The log-rank test is most powerful under proportional hazards (PH). In practice, non-PH patterns are often observed in clinical trials, such as in immuno-oncology; therefore, alter…
Going Digital: A Survey on Digitalization and Large Scale Data Analytics in Healthcare
Volker Tresp, J. Marc Overhage, Markus Bundschus +3
We provide an overview of the recent trends towards digitalization and large scale data analytics in healthcare. It is expected that these trends are instrumental in the dramatic c…